AlexanderKolevzonMD

Psychiatry • New York, NY

Child & Adolescent Psychiatry

Professor, Psychiatry and Pediatrics, Icahn School of Medicine

Join to view full profile

Dr. Kolevzon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kolevzon's full profile

Already have an account?

Office
1 Gustave L Levy Pl
# 1230
New York, NY 10029
Phone+1 212-659-9134

Fax+1 212-996-8931

Education & Training

Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalFellowship, Child and Adolescent Psychiatry, 2003 - 2005
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Psychiatry, 2000 - 2003
Tel Aviv University SacklerClass of 2000

Certifications & Licensure

NY State Medical License 2001 - 2025
FL State Medical License 2015 - 2017
American Board of Psychiatry and Neurology Psychiatry
American Board of Psychiatry and Neurology Child & Adolescent Psychiatry

Clinical Trials

Trichuris Suis Ova in Autism Spectrum Disorders Start of enrollment: 2012 Nov 01
Completed
Phase 1
Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome) Start of enrollment: 2012 Feb 01
Completed
Phase 2
A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome Start of enrollment: 2014 Jan 01
Completed
Phase 2
Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors Start of enrollment: 2014 Aug 01
Completed
Phase 2
A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder Start of enrollment: 2014 May 01
Terminated
Phase 2
Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome Start of enrollment: 2015 May 01
Recruiting
Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome Start of enrollment: 2016 Apr 29
Completed
Phase 2
AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy Start of enrollment: 2018 May 30
Completed
Phase 2
DDX3X Syndrome -The Seaver Autism Center for Research and Treatment is Characterizing DDX3X-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures. Start of enrollment: 2018 May 22
Recruiting
FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures. Start of enrollment: 2016 Mar 28
Recruiting
ADNP Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing ADNP-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures. Start of enrollment: 2017 Nov 14
Recruiting
Growth Hormone Treatment in Children With Phelan McDermid Syndrome Start of enrollment: 2019 Sep 13
Completed
Phase 2
Approach to Dance for Autism Start of enrollment: 2024 Aug 01
Not yet recruiting
Not Applicable
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1179 citations
Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism
F. Kyle Satterstrom, Jack A. Kosmicki, Jiebiao Wang, Michael S. Breen, Silvia De Rubeis
Cell. 2020-02-06
29 citations
FOXP1 syndrome: a review of the literature and practice parameters for medical assessment and monitoring
Reymundo Lozano, Catherine Gbekie, Paige M. Siper, Shubhika Srivastava, Jeffrey M. Saland
Journal of Neurodevelopmental Disorders. 2021-04-23
1462 citations
Functional impact of global rare copy number variation in autism spectrum disorders
Dalila Pinto, Alistair T. Pagnamenta, Lambertus Klei, Richard Anney, Daniele Merico
Nature. 2010-07-15

Press Mentions

Clinical Trial for Rare Genetic Disease Gets Assistance from Artificial IntelligenceNovember 4th, 2022
Ketamine Promising for Rare Condition Linked to AutismSeptember 13th, 2022
Ketamine May Be Effective in Treating Children with ADNP SyndromeSeptember 12th, 2022
Join now to see all

Grant Support

OPEN Label Risperidone In Children And Adolescents With Autistic DisorderNational Center For Research Resources2009
Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive BehaviorsNational Center For Research Resources2008